Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: An analysis of 1049 patients with cutaneous melanoma

Melanoma Research

Volumn 20, Issue 4, 2010, Pages 330-337

  Kunte, Christian ^a   Geimer, Till ^a   Baumert, Jens ^a,b   Konz, Birger ^a   Volkenandt, Matthias ^a   Flaig, Michael ^a   Ruzicka, Thomas ^a   Berking, Carola ^a   Schmid Wendtner, Monika H ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

melanoma; prognostic factors; sentinel lymph node; sentinel lymph node status; survival

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SCHOOL CHILD; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; ADOLESCENT; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 77954660257     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833ba9ff     Document Type: Article

References (37)

1. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75:2484-2491.
2. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995; 75:2492-2498.
3. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-1491.
4. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. WHO Melanoma Programme. Lancet 1998; 351:793-796.
5. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297:627-630.
6. Veronesi U, Cascinelli N. Response: lymph node dissection for stage I melanoma: the unresolved dilemma. CA Cancer J Clin 1982; 32:316-317. (Pubitemid 13200373)
7. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
8. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
9. Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications. Surg Oncol Clin N Am 2007; 16:35-54.
10. Vuylsteke RJ, Van Leeuwen PA, Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21:1057-1065.
11. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
12. Nathanson SD. Will the true sentinel node please stand? Ann Surg Oncol 1999; 6:514-516.
13. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 2003; 10:575-581.
14. Garbe C, Schadendorf D, StolzW, Volkenandt M, Reinhold U, Kortmann RD, et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008; 6 (Suppl 1):S9-S14.
15. Gonzalez U. Cloud over sentinel node biopsy: unlikely survival benefit in melanoma. Arch Dermatol 2007; 143:775-776.
16. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008; 5:18-23.
17. Thomas JM. Concerns relating to the conduct and statistical analysis of the multicenter selective lymphadenectomy trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg 2009; 62:442-446.
18. McMasters KM,Wong SL, Edwards MJ, Ross MI, Chao C, Noyes RD, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001; 130:151-156.
19. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol 2005; 141:1016-1022.
20. Landi G, Polverelli M, Moscatelli G, Morelli R, Landi C, Fiscelli O, et al. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol 2000; 14:35-45.
21. Mandala M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a singleinstitution prospectively collected database. Eur J Cancer 2009; 45:2537-2545.
22. Homolak D, Vucetic B, Puljiz Z, Blajc I, Vurnek Zivkovic M, Situm M. Our experience of melanoma thickness as a predictor of outcome of sentinel node biopsy. Coll Antropol 2008; 32 (Suppl 2):57-60.
23. Testori A, De Salvo GL, Montesco MC, Trifiro G, Mocellin S, Landi G, et al. Clinical considerations on sentinel node biopsy in melanoma from an italian multicentric study on 1313 patients (SOLISM-IMI). Ann Surg Oncol 2009; 16:2018-2027.
24. Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 2002; 26:47-55.
25. Wagner JD, Gordon MS, Chuang TY, Coleman JJ III, Hayes JT, Jung SH, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89:453-462.
26. Busam KJ, Pulitzer M. Sentinel lymph node biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors? Adv Anat Pathol 2008; 15:253-262.
27. Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G,Wolff K, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005; 92:662-667.
28. Cecchi R, Buralli L, Innocenti S, Seghieri G, De Gaudio C. Sentinel lymph node biopsy in patients with thick ( = 4 mm) melanoma: a single-centre experience. J Eur Acad Dermatol Venereol 2007; 21:758-761.
29. Gutzmer R, Satzger I, Thoms KM, Volker B, Mitteldorf C, Kapp A, et al. Sentinel lymph node status is the most important prognostic factor for thick (Z4 mm) melanomas. J Dtsch Dermatol Ges 2008; 6:198-203.
30. Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004; 17:747-755.
31. Ollila DW, Ashburn JH, Amos KD, Yeh JJ, Frank JS, Deal AM, et al. Metastatic melanoma cells in the sentinel node cannot be ignored. J Am Coll Surg 2009; 208:924-929.
32. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004; 11:162S-168S.
33. Van Akkooi AC, Nowecki ZI, Voit C, Schafer-Hesterberg G, Michej W, de Wilt JH, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248:949-955.
34. Van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Nieweg OE. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg 2009; 249:1003-1007.
35. Jakub JW, Huebner M, Shivers S, Nobo C, Puleo C, Harmsen WS, et al. The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node. Ann Surg Oncol 2009; 16:2245-2251.
36. Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007; 14:906-912.
37. Schmid-Wendtner MH, Baumert J, Schmidt M, Plewig G, Volkenandt M, Holzel D. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res 2001; 11:619-626.